VTVT earnings analysis
What we found in VTVT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
vTv Therapeutics reported first-quarter results for 2026 with significant revenue generation of $36.8 million, a stark increase from no revenue in the prior year. The company also recorded a net income of $24.1 million, reversing last year's loss and demonstrating strong growth momentum. Management remains optimistic about ongoing clinical trials and future revenue potential from its drug candidates.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Substantial Revenue Growth
- Revenue for Q1 2026 was $36.8 million, compared to $0 in Q1 2025, marking a significant increase.
- Positive EPS Shift
- Diluted EPS for Q1 2026 was $1.65, a significant turnaround from a loss of $0.77 in Q1 2025.
- Operating Income Growth
- Operating income improved to $23.3 million in Q1 2026, up from a loss of $6.5 million in Q1 2025.
- Increased R&D Investment
- R&D expenses rose to $9.0 million in Q1 2026, up 217.2% from $2.8 million in Q1 2025.
- Strong Cash Position
- As of March 31, 2026, cash and cash equivalents totaled $98.1 million.
- Increased Interest Income
- Interest income in Q1 2026 was $0.8 million, up from $0.3 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Clinical Trial Risks
- The success of pivotal trials for cadisegliatin remains uncertain, with lengthy timelines and regulatory hurdles.
- Dependence on Cadisegliatin
- The company's future revenue is highly dependent on the success of cadisegliatin, limiting diversification.
- Need for Additional Capital
- vTv anticipates needing substantial additional funding to continue clinical trials and operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.65
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · March 10, 2026
- vTv is a late-stage biotech focused on an oral, liver‑selective glucokinase activator, cadisegliatin (TTP399). The company resumed its Phase 3 CATT1 trial in May 2025 (150 patients; 1:1:1 randomization, 50 per arm)…
- 10-Q · May 15, 2025
- vTv reported no revenue for Q1 2025 and a net loss attributable to vTv Therapeutics Inc. of $5,092 (three months ended March 31, 2025), or $(0.77) per share, versus net loss $4,865 and $(1.17) per share in Q1 2024. Cash…
- 10-Q · August 8, 2024
- vTv reported Q2 results showing no revenue for the quarter and a narrowing loss: net loss attributable to vTv was $(5,180) for the three months ended June 30, 2024 (versus $(5,619) in Q2 2023) and net loss per Class A…
- 10-Q · May 9, 2024
- vTv reported Q1 2024 revenue of $1,000,000 (first quarter with revenue vs $0 prior year) and GAAP net loss attributable to vTv Therapeutics Inc. of $4,865,000 (EPS $(1.17)). Cash increased materially to $52,255,000 at…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VTVT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever